Using Carboxymethl Starch Sodium Solution for the Treatment of Children with Cough Variation Asthma

Objective To analysis the clinical characterist ics of children with cough variation asthma （CVA） who received treatments with Carboxymethl starch sodium solution and inhaled Glucocorticoid budesonide． Methods A total of 96 children with CVA were divided into two g rou p randomly. The control group (n=49) received inhaled budesonide treatment ( 500 μg/times in 1-5 years old children, 1 mg/times and 2 times/day in 6-14 ye a rs old children over a 12 week period). The children in treatment group (n=4 7) were given carboxymethl starch sodium solution (3 mL/times in 1-3 years old children, 5 mL/times in 4-7 years old children, 7 mL/times in 8-14 years old c hildren, 3 times/day) in addition to the inhaled budesonide treatment. Observati ons were made on clinical therapeutic effects, cough score and the level of IgE 4 weeks, 8 weeks and 12 weeks after the treatments, respectively. Recurrence rat e and adv erse reactions were investigated. Results Compared with the con trol group, the treatment group had significantly improved clinical characterist ics after 8 weeks and 12 weeks of treatments (P<0.05), and reduced cough sco res after 4 weeks, 8 weeks and 12 weeks of treatments (P<0.05). The IgE leve l of the children in the treatment group was significantly lower than the contro ls after 12 weeks of treatments (P<0.05). The treatment group also had significantly lower recurrence rate and adverse reactions than the controls ( P<0.05)．Conclusion Carboxymethl starch sodium solution can boost the clinical efficiency of inhaled budesonide in the treatment of childre n with cough variant asthma. It is safe and effectual.